Dermatology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy.
Pathology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy.
Vet Dermatol. 2022 Apr;33(2):149-e42. doi: 10.1111/vde.13053. Epub 2022 Jan 11.
Oclacitinib administered at the licensed dose twice daily for two weeks and then once daily as required is recommended for the treatment of atopic dogs. In some cases, the once-daily regimen is insufficient to control the clinical signs.
To provide preliminary safety and efficacy data on the prolonged twice-daily administration of oclacitinib in atopic dogs.
Fifty-three client-owned atopic dogs.
The medical records of dogs with atopic dermatitis treated with oclacitinib twice daily for more than two weeks were reviewed retrospectively. Animal details, treatment dose and duration, concurrent diseases, adjunctive medications and possible adverse events were recorded. Treatment efficacy was assessed retrospectively and, when available, the selected blood parameters before and during the treatment were compared. Statistical analyses of the collected data were performed.
The median treatment duration was 113 days. Excellent-to-good efficacy was observed in 38 dogs (72%), including 24 of 33 dogs that failed to respond to the once-daily regimen. Eight dogs showed a poor response despite the addition of systemic glucocorticoids. Pyoderma, gastrointestinal signs and otitis externa were the most frequent adverse events recorded whilst on treatment. Blood tests performed in 35 dogs showed slightly decreased leucocyte, neutrophil, eosinophil and monocyte counts that remained within the reference ranges in most cases. Three dogs developed hypercholesterolemia.
Prolonged twice-daily administration of oclacitinib generally was well-tolerated and was effective in most of the treated dogs. Regular clinical evaluation and blood tests are advisable for this treatment regimen.
奥昔替尼被批准的剂量，每日两次，持续两周，然后按需每日一次，用于治疗特应性犬。在某些情况下，每日一次的方案不足以控制临床症状。
提供奥昔替尼在特应性犬中延长每日两次给药的初步安全性和疗效数据。
53 只患有特应性皮炎的客户拥有的犬。
回顾性审查了接受奥昔替尼每日两次治疗超过两周的特应性皮炎犬的病历。记录了动物详细信息、治疗剂量和持续时间、合并症、辅助药物和可能的不良反应。回顾性评估治疗效果，在治疗期间，当有可用数据时，比较了之前选择的血液参数。对收集的数据进行了统计分析。
中位治疗持续时间为 113 天。38 只犬（72%）疗效良好，其中 24 只对每日一次的方案无反应的犬疗效良好。尽管加用全身皮质类固醇，8 只犬的反应不佳。在治疗期间，最常见的不良反应是脓皮病、胃肠道症状和外耳炎。对 35 只犬进行的血液检查显示白细胞、中性粒细胞、嗜酸性粒细胞和单核细胞计数略有下降，但在大多数情况下仍在参考范围内。三只狗出现高胆固醇血症。
奥昔替尼延长每日两次给药通常耐受良好，大多数治疗犬有效。建议对该治疗方案进行定期临床评估和血液检查。
